Journal List > Intest Res > v.21(2) > 1516082662

TOOLS
Oh, Hong, Ham, Lee, Park, Yang, Yoon, Kim, Choi, Ye, and on behalf of the Korean Association for the Study of Intestinal Diseases: Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Corrigendum

Intest Res 2023;21(2):273-273.

Published online: 28 April 2023

DOI: https://doi.org/10.5217/ir.2021.00173.e

Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study

Kyunghwan Oh1, Hee Seung Hong1, Nam Seok Ham1, Jungbok Lee2, Sang Hyoung Park1, 3, 4, Suk-Kyun Yang1, 3, 4, Hyuk Yoon5, You Sun Kim6, Chang Hwan Choi7, Byong Duk Ye1, 3, 4; on behalf of the Korean Association for the Study of Intestinal Diseases

1Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

4Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea

5Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

6Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea

7Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

© Copyright 2023. Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Intest Res 2023;21(1):137-147
In the article entitled “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,”1 the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold.
“Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/29 (59.2%) patients at week 8 and 26 (53.1%)/34 (69.4%) patients at week 20, respectively (Fig. 2).”

REFERENCES

1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intest Res. 2023; 21:137–147.
crossref
TOOLS
Similar articles